Скачать или смотреть Sacituzumab Exploring its Role in Cancer Research and the Rise of Biosimilars

https://www.assaygenie.com/anti-trop2...

Main Ideas and Facts:

1. Understanding Sacituzumab:

Definition: Sacituzumab is described as an "innovative antibody-drug conjugate (ADC) that combines targeted immunotherapy with the precision of modern chemotherapy."
Target and Payload: It consists of a monoclonal antibody specifically targeting Trop-2, a cell surface protein highly expressed in many cancers, linked to SN-38, the active metabolite of irinotecan and a potent topoisomerase I inhibitor.
Mechanism: The dual-action design allows sacituzumab to deliver chemotherapy directly to cancer cells with precision. "By leveraging this dual-action design, sacituzumab delivers chemotherapy directly to cancer cells with remarkable precision."
Trop-2 as a Target: Trop-2 is highlighted as an "attractive therapeutic target" due to its overexpression in various malignancies, including "triple-negative breast cancer (TNBC), hormone-receptor-positive breast cancer, urothelial carcinoma, and some gastrointestinal cancers."

Targeted Delivery: Upon binding to Trop-2, sacituzumab is internalized by the tumor cell, leading to the release of the cytotoxic payload, SN-38, directly within the cancer cell. "This mechanism allows for effective tumor cell death while sparing healthy tissues, leading to fewer systemic side effects compared to conventional chemotherapy."
Precision Oncology: The development of sacituzumab reflects the growing emphasis on "precision oncology," aiming for maximized therapeutic efficacy with minimized harm to healthy tissues.
Hope for Difficult-to-Treat Cancers: Sacituzumab offers "new hope for patients with difficult-to-treat cancers, particularly those with limited options in advanced stages."

2. Mechanism of Action of Sacituzumab:

Selective Targeting: Sacituzumab's primary mechanism involves selectively targeting and killing cancer cells while minimizing harm to healthy tissues.
Trop-2 Binding and Internalization: The monoclonal antibody in sacituzumab binds to Trop-2 with high affinity. "After binding, the drug-antibody complex is internalized into the cancer cell, where it undergoes degradation in lysosomes."
SN-38 Release and Function: Lysosomal degradation releases SN-38 within the cancer cell. "SN-38 functions as a topoisomerase I inhibitor, disrupting DNA replication and leading to cell death, particularly in rapidly dividing tumor cells."
Enhanced Efficacy and Reduced Toxicity: This targeted delivery system "significantly enhances the efficacy of chemotherapy while reducing systemic toxicity and side effects commonly associated with traditional chemotherapeutic regimens."

Breakthrough in Oncology: Sacituzumab's mechanism has positioned it as a "breakthrough in oncology," especially for cancers with high Trop-2 expression like TNBC and urothelial carcinoma.
Advancement in Targeted Therapies: The precision delivery system exemplifies "the advancements in targeted cancer therapies."